Back to today’s briefing

Story perspectives

EMA Reassesses Leqembi's Safety for Alzheimer's Treatment

1/31/2025

34 3

Summary

Story summary

The European Medicines Agency (EMA) is set to reassess safety data for Leqembi (lecanemab), a drug aimed at treating mild cognitive impairment and early Alzheimer's. Initially turned down over safety worries, it was later approved for patients with limited APOE4 gene copies. Now, the European Commission seeks a deeper dive into its safety profile.

1 of 1

Story summary

The European Medicines Agency (EMA) is set to reassess safety data for Leqembi (lecanemab), a drug aimed at treating mild cognitive impairment and early Alzheimer's. Initially turned down over safety worries, it was later approved for patients with limited APOE4 gene copies. Now, the European Commission seeks a deeper dive into its safety profile.